Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06797622
Overview
The purpose of this study was to explore the predictive value of the heterogeneity of 68Ga-FAPI PET-CT uptake before treatment on the response of T-DXd treatment in patients with brain metastases of HER2-positive breast cancer. The patient underwent 68Ga-FAPI PET-CT examinations within 2 weeks before and after 2 cycles of T-DXd treatment. Heterogeneity index, SUVmax, SUVmean and other uptake values were collected to investigate the association with efficacy of T-DXd.
Sponsor
Fudan University
Phase
Phase 2
Contacts
Biyun Wang (Professor)
wangbiyun0107@hotmail.com
18017312387
ClinicalTrials.gov
NCT06797622Drug / Compound
Help us improve your experience